HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
Stocks · News reference
Sagimet Biosciences shares are trading higher after the company announced 52-week results from the Phase 3 ASC40-304 OLE trial of denifanstat for acne. The company suspended its at-the-market sale through Leerink Partners and announced the pricing of its $115 million offering of 8,750,010 shares at $10.00 per share.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading